Novel approaches are needed to develop tomorrow's antibacterial therapies - Wikidata - wikimedia - TriplyDB

Novel approaches are needed to develop tomorrow's antibacterial therapies

Novel approaches are needed to develop tomorrow's antibacterial therapies

http://www.wikidata.org/entity/Q35140751

about

Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient The anti-Staphylococcus aureus activity of the phenanthrene fraction from fibrous roots of Bletilla striata Urinary Tract Infection: Pathogenesis and Outlook.Challenges and solutions for clinical development of new antibacterial agents: results of a survey among pharmaceutical industry professionals.Auranofin-loaded nanoparticles as a new therapeutic tool to fight streptococcal infections.PL3 Amidase, a Tailor-made Lysin Constructed by Domain Shuﬄing with Potent Killing Activity against Pneumococci and Related Species Inosine 5'-monophosphate dehydrogenase inhibitors as antimicrobial agents: recent progress and future perspectives.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.Update in Critical Care 2015.Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) restores carbapenem susceptibility to NDM-1-positive pathogens in vitro and in vivo.Towards Profiles of Resistance Development and Toxicity for the Small Cationic Hexapeptide RWRWRW-NH2.Development of botanicals to combat antibiotic resistance.An update on the pharmacotherapeutic management of lower respiratory tract infections.[New antibacterial agents on the market and in the pipeline].Mapping Protein-Protein Interactions of the Resistance-Related Bacterial Zeta Toxin-Epsilon Antitoxin Complex (ε₂ζ₂) with High Affinity Peptide Ligands Using Fluorescence Polarization.A quinolinol-based small molecule with anti-MRSA activity that targets bacterial membrane and promotes fermentative metabolism.Synthesis and Microbiological Evaluation of Novel Tetracyclic Fluoroquinolones.In 2035, will all bacteria be multidrug resistant? We are not sure.Mugs of the bugs: The most wanted ones.Peptidoglycan Recognition Protein 3 Does Not Alter the Outcome of Pneumococcal Pneumonia in Mice.An environmentally benign dual action antimicrobial: quaternized chitosan/sodium alga acid multilayer films and silver nanoparticles decorated on magnetic nanoparticles.

P2860

Q26752680-5B59BEE1-D376-4E24-B006-99360144EE95 Q28818270-CB43D933-C0D8-469F-9571-4D2F7CCFE635 Q30244953-04E3B7F1-FE0A-498C-AFAC-A9E04ED3B2E9 Q35746206-CC8D08CE-6C76-4294-A7CA-24500D697E5C Q36500235-4DBFFEA9-BB80-4C67-8ECE-43C7617751FC Q37131742-CDBEB90C-2FA2-4C3A-9062-C2ABFF5F34D0 Q38558374-7386017A-4FEF-4DB4-A58C-C12C7A3475FB Q38672016-93442265-8066-42F1-BA56-FBF82E67E637 Q38883355-25192402-C514-4112-9FCC-95E9794A52CD Q39080538-FF31CF93-CF96-403C-AACB-0178047661CF Q39401886-3FB05551-B51B-48D9-9B3C-126376E57AA9 Q40059294-AC72AE61-4DC9-4685-913B-26C098092145 Q40222424-62631775-E898-4935-A3C8-B13FE7693EE3 Q40948209-D79BEBB4-4575-49E6-BFB1-172DD2821515 Q42398396-F72AA3AA-9B05-498B-A797-AD2AC351CB7A Q47836437-D971B54E-0036-4F74-BAED-8F9326F86EB3 Q48110031-A200774D-6B61-422C-8B3B-12DFD54AADCE Q48141240-86F7C082-FCAF-4691-A43A-898155BE986A Q48271598-D6038FAD-794A-4646-B7D9-AE194D47C3BE Q49957016-E1182142-7B35-4D0F-AE1A-DD4C85EA47E6 Q50224219-44B3391A-C7C4-4F29-8014-DDF1EEB5212B

P2860

Novel approaches are needed to develop tomorrow's antibacterial therapies

http://www.wikidata.org/entity/Q35140751

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Novel approaches are needed to develop tomorrow's antibacterial therapies

@ast

Novel approaches are needed to develop tomorrow's antibacterial therapies

@en

type

label

Novel approaches are needed to develop tomorrow's antibacterial therapies

@ast

Novel approaches are needed to develop tomorrow's antibacterial therapies

@en

prefLabel

Novel approaches are needed to develop tomorrow's antibacterial therapies

@ast

Novel approaches are needed to develop tomorrow's antibacterial therapies

@en

P1433

Q35140751-8735845E-C195-4821-BED8-964D254FC67B

P1476

Q35140751-764B6313-714E-43CE-B3A7-DC9815D8BB3E

P2093

Q35140751-55387B8D-E0BC-4018-B774-20D912E45F9D

Q35140751-D8E6B4E3-738C-40D7-ABBF-3EDED0E6279F

Q35140751-FC028116-5F99-4AE3-885C-52E06E738672

P2860

Q35140751-01562B09-C266-4718-A118-B5C545B3D53F

Q35140751-09AAB38E-BD2D-487E-B096-9929733D374D

Q35140751-0BBC8936-D7FF-41CF-8332-0305E51A8E1A

Q35140751-0CCE6F5F-BA0D-4D95-80FD-7AAFE870438F

Q35140751-256F13D9-66EE-47BC-A4AD-E0BFEAEC46E6

Q35140751-289BA777-35E7-49B2-AA61-22B01B969129

Q35140751-348A4A30-65E7-4CD6-B650-7DA3A9550004

Q35140751-435663CB-DBE5-4D5A-B1F1-8DDB824D46FC

Q35140751-45680389-A63C-4634-A29F-1D5768F0618C

Q35140751-525A02AC-0066-4B8C-A31D-122475A45B4A

P304

Q35140751-CACFBEBD-CF0F-4358-AEB8-08DF96FC007C

P31

Q35140751-3B9C2D5E-672D-466B-A287-C5A923F5DCF5

P356

Q35140751-FFF5C6DD-3E91-4701-AE7A-17FAAAABD35E

P407

Q35140751-33C7C77C-0C7D-4A65-8591-67B98BA23DBD

P433

Q35140751-AA73D18A-9674-4A26-A836-A0C42AE37A3E

P478

Q35140751-3163264F-05DA-4773-9F10-2CD775E3EB3A

P50

Q35140751-813A7D94-E46F-4809-BBDC-3E24139DFDCE

P577

Q35140751-5F31F548-84AA-4526-96E3-0E1828E54ED9

P698

Q35140751-7CE33215-82F6-4EAF-87FD-2AB780281074

P932

Q35140751-45147FAB-5823-41B3-9683-B5445ABE73E6

P356

RCCM.201410-1894OE

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Novel approaches are needed to develop tomorrow's antibacterial therapies

@en

P2093

Brad Spellberg

http://www.w3.org/2001/XMLSchema#string

David N Gilbert

http://www.w3.org/2001/XMLSchema#string

John Bartlett

http://www.w3.org/2001/XMLSchema#string

P2860

Combating antimicrobial resistance: policy recommendations to save lives

Non-traditional antibacterial screening approaches for the identification of novel inhibitors of the glyoxylate shunt in gram-negative pathogens

Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia.

Antibiotic judo: working gently with prescriber psychology to overcome inappropriate use.

The role of the microbiome in exacerbations of chronic lung diseases.

Predictors of hospital mortality among septic ICU patients with Acinetobacter spp. bacteremia: a cohort study.

Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Efficacy of anti-inflammatory or antibiotic treatment in patients with non-complicated acute bronchitis and discoloured sputum: randomised placebo controlled trial.

Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia

Topographical continuity of bacterial populations in the healthy human respiratory tract.

P304

135-140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.201410-1894OE

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

191

http://www.w3.org/2001/XMLSchema#string

P50

Richard G. Wunderink

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25590154

http://www.w3.org/2001/XMLSchema#string

P932

4347440

http://www.w3.org/2001/XMLSchema#string